WHO ICTRP trial
Study to evaluate the efficacy and safety of fruquintinib as maintenance therapy…
ChiCTR2400083670 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2400083670 |
|---|---|
| Public title | Study to evaluate the efficacy and safety of fruquintinib as maintenance therapy after second-line treatment in patients with advanced colorectal cancer |
| Scientific title | Study to evaluate the efficacy and safety of fruquintinib as maintenance therapy after second-line treatment in patients with advanced colorectal cancer |
| Primary sponsor | Zibo Municipal Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | Colorectal cancer |
| Interventions | Experimental group:Stage I: fuquinitinib Stage 2: fuquinitinib combined with chemotherapy or PD-1 |
| Registration date | Apr 30, 2024 |
| Target size | Experimental group:20 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: